2021
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.
Ahmed K, Kim Y, Arrington J, Kim S, DeJesus M, Soyano A, Armaghani A, Costa R, Khong H, Rosa M, Caudell J, Diaz R, Robinson T, Etame A, Tran N, Sahebjam S, Soliman H, Forsyth P, Yu H, Han H. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study. Journal Of Clinical Oncology 2021, 39: e14010-e14010. DOI: 10.1200/jco.2021.39.15_suppl.e14010.Peer-Reviewed Original ResearchBreast cancer brain metastasesCancer brain metastasesProgression-free survivalBrain metastasesStereotactic radiosurgeryBrain metastasis controlStudy therapyControl rateMetastasis controlCertain breast cancer patientsNeuro-Oncology Brain MetastasesSystemic progression-free survivalDose of nivolumabNeurologic adverse eventsImmune checkpoint inhibitionPhase Ib studyPhase Ib trialSolid Tumors criteriaResponse Evaluation CriteriaKey eligibility criteriaTumor control rateFeasible treatment optionBreast cancer patientsBrain metastasis managementExtracranial disease
2020
RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION
Thawani C, Mills M, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION. Neuro-Oncology 2020, 22: ii181-ii182. PMCID: PMC7651564, DOI: 10.1093/neuonc/noaa215.757.Peer-Reviewed Original ResearchBreast cancer subtypesBreast cancer brain metastasesBrain metastasis diagnosisCancer brain metastasesBrain metastasesStereotactic radiationOverall survivalClinical outcomesCancer subtypesHR-/HER2TN patientsMetastasis diagnosisHormone receptorsBreast cancer patientsBrain metastasis controlBreast brain metastasesOS ratesClinical chartsInstitutional seriesMedian ageSystemic metastasesInstitutional registryCancer patientsRadiologic examinationDisease progression